Interaction between mineralocorticoid receptor and epidermal growth factor receptor signaling

Molecular and Cellular Endocrinology

Volumn 350, Issue 2, 2012, Pages 235-241

  Grossmann, Claudia ^a   Gekle, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Epidermal growth factor receptor; Mineralocorticoid receptor; Transactivation; Vascular function; Vascular remodelling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MINERALOCORTICOID RECEPTOR;

AGING; CELL MIGRATION; CELL PROLIFERATION; DIMERIZATION; EGFR GENE; FIBROSIS; GENE; GENE DELETION; GENE EXPRESSION; HOMEOSTASIS; INFLAMMATION; LIGAND BINDING; MR GENE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SMOOTH MUSCLE FIBER; SODIUM ABSORPTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

AGING; ANIMALS; BLOOD VESSELS; CELL PROLIFERATION; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; PROTEIN BINDING; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84856345106     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.07.045     Document Type: Review

References (75)

1. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A., Polly M.L., McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003, 63:1791-1800.
2. Briet M., Schiffrin E.L. Aldosterone: effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 2010, 6:261-273.
3. Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 1992, 120:893-901.
4. Brilla C.G., Zhou G., Matsubara L., Weber K.T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin ii and aldosterone. J. Mol. Cell. Cardiol. 1994, 26:809-820.
5. Callera G.E., Montezano A.C.I., Yogi A., Tostes R.C., He Y., Schiffrin E.L., Touyz R.M. C-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive Rats. Hypertension 2005, 46:1032-1038.
6. Callera G.E., Touyz R.M., Tostes R.C., Yogi A., He Y., Malkinson S., Schiffrin E.L. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005, 45:773-779.
7. Dorrance A.M., Osborn H.L., Grekin R., Webb R.C. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281:R944-R950.
8. Dorrance A.M., Rupp N.C., Nogueira E.F. Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 2006, 47:590-595.
9. Drumm K., Kress T.R., Gassner B., Krug A.W., Gekle M. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell. Physiol. Biochem. 2006, 17:21-28.
10. Fels J., Callies C., Kusche-Vihrog K., Oberleithner H. Nitric oxide release follows endothelial nanomechanics and not vice versa. Pflugers. Arch. 2010, 460:915-923.
11. Flamant M., Tharaux P.L., Placier S., Henrion D., Coffman T., Chatziantoniou C., Dussaule J.C. Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J. 2003, 17:327-329.
12. Florian,J.A., Dorrance,A., Webb,R.C., and Watts,S.W., 2001. Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am. J. Physiol. Regul. Integr. Comp. Physiol. JID - 100901230 281,R878-R886.
13. Funder J.W. The nongenomic actions of aldosterone. Endocr. Rev. 2005, 26:313-321.
14. Ganong W.F., Mulrow P.J. Rate of change in sodium and potassium excretion after injection of aldosterone into the aorta and renal artery of the dog. Am. J. Physiol. 1958, 195:337-341.
15. Gekle M., Freudinger R., Mildenberger S., Silbernagl S. Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am. J. Physiol. Renal Physiol. 2002, 282:F669-F679.
16. Gekle M., Grossmann C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?. Pfluegers Arch. Eur. J. Physiol. 2009, 458:231-246.
17. Gekle M., Mildenberger S., Freudinger R., Grossmann C. Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone. Pfluegers Arch. Eur. J. Physiol. 2007, 454:403-413.
18. Gilbert K.C., Brown N.J. Aldosterone and inflammation. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:199-204.
19. Griol-Charhbili V., Fassot C., Messaoudi S., Perret C., Agrapart V., Jaisser F. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011, 57:238-244.
20. Gros R., Ding Q., Sklar L.A., Prossnitz E.E., Arterburn J.B., Chorazyczewski J., Feldman R.D. GPR30 expression is required for the mineralocorticoid receptorγçôindependent rapid vascular effects of aldosterone. Hypertension 2011, 57:442-451.
21. Grossmann C., Benesic A., Krug A.W., Freudinger R., Mildenberger S., Gassner B., Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol. Endocrinol. 2005, 19:1697-1710.
22. Grossmann C., Freudinger R., Mildenberger S., Krug A.W., Gekle M. Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption. Am. J. Physiol. Renal Physiol. 2004, 286:F1226-F1231.
23. Grossmann C., Freudinger R., Mildenberger S., Husse B., Gekle M. EF domains are sufficient for nongenomic mineralocorticoid receptor actions. J. Biol. Chem. 2008, 283:7109-7116.
24. Grossmann C., Husse B., Mildenberger S., Schreier B., Schuman K., Gekle M. Colocalization of mineralocorticoid and EGF receptor at the plasma membrane. Biochimica. et Biophys. Acta (BBA) - Mol. Cell Res. 2010, 1803:584-590.
25. Grossmann C., Krug A.W., Freudinger R., Mildenberger S., Voelker K., Gekle M. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1790-E1800.
26. Hilleman D.E., Lucas B.D. Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?. Pharmacotherapy 2004, 24:1064-1076.
27. Hsieh J.K., Kletsas D., Clunn G., Hughes A.D., Schachter M., Demoliou-Mason C. P53, p21(WAF1/CIP1), and MDM2 involvement in the proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2000, 20:973-981.
28. Huang S., Zhang A., Ding G., Chen R. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am. J. Physiol. Renal Physiol. 2009, 296:F1323-F1333.
29. Ishizawa K., Izawa Y., Ito H., Miki C., Miyata K., Fujita Y., Kanematsu Y., Tsuchiya K., Tamaki T., Nishiyama A., et al. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 2005, 46:1046-1052.
30. Kagiyama S., Eguchi S., Frank G.D., Inagami T., Zhang Y.C., Phillips M.I. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002, 106:909-912.
31. Kim J., Lee C.K., Park H.J., Kim H.J., So H.H., Lee K.S., Lee H.M., Roh H.Y., Choi W.S., Park T.K., et al. Epidermal growth factor induces vasoconstriction through the phosphatidylinositol 3-kinase-mediated mitogen-activated protein kinase pathway in hypertensive rats. J. Pharmacol. Sci. 2006, 101:135-143.
32. Krug A.W., Allenhofer L., Monticone R., Spinetti G., Gekle M., Wang M., Lakatta E.G. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 2010, 55:1476-1483.
33. Krug A.W., Grossmann C., Schuster C., Freudinger R., Mildenberger S., Govindan M.V., Gekle M. Aldosterone stimulates epidermal growth factor receptor (EGFR) expression. J. Biol. Chem. 2003, 278:43060-43066.
34. Krug A.W., Pojoga L.H., Williams G.H., Adler G.K. Cell membrane-associated mineralocorticoid receptors?. Hypertension 2011, 57:1019-1025.
35. Kusche-Vihrog K., Urbanova K., Blanque A., Wilhelmi M., Schillers H., Kliche K., Pavenstadt H., Brand E., Oberleithner H. C-reactive protein makes human endothelium stiff and tight. Hypertension 2011, 57:231-237.
36. Limor R., Kaplan M., Sharon O., Knoll E., Naidich M., Weisinger G., Keidar S., Stern N. Aldosterone up-regulates 12- and 15-lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells. J. Cell. Biochem. 2009, 108:1203-1210.
37. Mazak I., Fiebeler A., Muller D.N., Park J.K., Shagdarsuren E., Lindschau C., Dechend R., Viedt C., Pilz B., Haller H., et al. Aldosterone potentiates angiotensin ii-induced signaling in vascular smooth muscle cells. Circulation 2004, 109:2792-2800.
38. McEneaney V., Dooley R., Harvey B.J., Thomas W. Protein kinase D stabilizes aldosterone-induced ERK1/2 MAP kinase activation in M1 renal cortical collecting duct cells to promote cell proliferation. J. Steroid Biochem. Mol. Biol. 2010, 118:18-28.
39. McEneaney V., Dooley R., Harvey B.J., Thomas W. Protein kinase D stabilizes aldosterone-induced ERK1/2 MAP kinase activation in M1 renal cortical collecting duct cells to promote cell proliferation. J. Steroid. Biochem. Mol. Biol. 2010, 118:18-28.
40. McEneaney V., Harvey B.J., Thomas W. Aldosterone rapidly activates protein kinase D via a mineralocorticoid receptor/EGFR trans-activation pathway in the M1 kidney CCD cell line. J. Steroid Biochem. Mol. Biol. 2007, 107:180-190.
41. McEneaney V., Harvey B.J., Thomas W. Aldosterone regulates rapid trafficking of epithelial sodium channel subunits in renal cortical collecting duct cells via protein kinase D activation. Mol. Endocrinol. 2008, 22:881-892.
42. Mihailidou A.S., Mardini M., Funder J.W. Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology 2004, 145:773-780.
43. Min L.J., Mogi M., Iwanami J., Li J.M., Sakata A., Fujita T., Tsukuda K., Iwai M., Horiuchi M. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc. Res 2007, 76:506-516.
44. Min L.J., Mogi M., Li J.M., Iwanami J., Iwai M., Horiuchi M. Aldosterone and angiotensin ii synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res. 2005, 97:434-442.
45. Montezano A.C., Callera G.E., Yogi A., He Y., Tostes R.C., He G., Schiffrin E.L., Touyz R.M. Aldosterone and angiotensin ii synergistically stimulate migration in vascular smooth muscle cells through c-src-regulated redox-sensitive RhoA pathways. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1511-1518.
46. Nagai Y., Miyata K., Sun G.P., Rahman M., Kimura S., Miyatake A., Kiyomoto H., Kohno M., Abe Y., Yoshizumi M., et al. aldosterone stimulates collagen gene expression and synthesis via activation of erk1/2 in rat renal fibroblasts. Hypertension 2005, 46:1039-1045.
47. Nakamura Y., Suzuki S., Suzuki T., Ono K., Miura I., Satoh F., Moriya T., Saito H., Yamada S., Ito S., et al. MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. Am. J. Pathol. 2006, 169:362-371.
48. Nakano S., Kobayashi N., Yoshida K., Ohno T., Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, nad(p)h oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens. Res. 2005, 28:925-936.
49. Nishiyama,A., Yao,L., Fan,Y., Kyaw,M., Kataoka,N., Hashimoto,K., Nagai,Y., Nakamura,E., Yoshizumi,M., Shokoji,T. et al., 2005. Involvement of Aldosterone and Mineralocorticoid Receptors in Rat Mesangial Cell Proliferation and Deformability. Hypertension 01-07.
50. Northcott C., Florian J.A., Dorrance A., Watts S.W. Arterial epidermal growth factor receptor expression in deoxycorticosterone acetate-salt hypertension. Hypertension 2001, 38:1337-1341.
51. Oberleithner H., Riethmuller C., Schillers H., MacGregor G.A., de Wardener H.E., Hausberg M. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc. Natl. Acad. Sci. USA 2007, 104:16281-16286.
52. Oberleithner H., Schneider S.W., Albermann L., Hillebrand U., Ludwig T., Riethm++ller C., Shahin V., Sch+ñfer C., Schillers H. Endothelial cell swelling by aldosterone. J. Mem. Biol. 2003, 196:163-172.
53. Osmond J.M., Rigsby C.S., Dorrance A.M. Is the mineralocorticoid receptor a potential target for stroke prevention?. Clin. Sci. (Lond.) 2008, 114:37-47.
54. Otani H., Otsuka F., Inagaki K., Takeda M., Miyoshi T., Suzuki J., Mukai T., Ogura T., Makino H. Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. Am. J. Physiol. Renal Physiol. 2007, 292:F1513-F1525.
55. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348:1309-1321.
56. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341:709-717.
57. Pitt B., Reichek N., Willenbrock R., Zannad F., Phillips R.A., Roniker B., Kleiman J., Krause S., Burns D., Williams G.H. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4e-left ventricular hypertrophy study. Circulation 2003, 108:1831-1838.
58. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
59. Qin W., Rudolph A.E., Bond B.R., Rocha R., Blomme E.A.G., Goellner J.J., Funder J.W., McMahon E.G. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003, 93:69-76.
60. Rickard A.J., Morgan J., Tesch G., Funder J.W., Fuller P.J., Young M.J. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009, 54:537-543.
61. Rocha R., Rudolph A.E., Frierdich G.E., Nachowiak D.A., Kekec B.K., Blomme E.A., McMahon E.G., Delyani J.A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H1802-H1810.
62. Sinphitukkul K., Eiam-Ong S., Manotham K., Eiam-Ong S. Nongenomic effects of aldosterone on renal protein expressions of pEGFR and pERK1/2 in rat kidney. Am. J. Nephrol. 2010, 33:111-120.
63. Sokol S.I., Portnay E.L., Curtis J.P., Nelson M.A., Hebert P.R., Setaro J.F., Foody J.M. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004, 63:208-213.
64. Sun G.P., Kohno M., Guo P., Nagai Y., Miyata K., Fan Y.Y., Kimura S., Kiyomoto H., Ohmori K., Li D.T., et al. Involvements of Rho-Kinase and TGF-beta pathways in aldosterone-induced renal injury. J. Am. Soc. Nephrol. 2006, 17:2193-2201.
65. Terada Y., Kobayashi T., Kuwana H., Tanaka H., Inoshita S., Kuwahara M., Sasaki S. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J. Am. Soc. Nephrol. 2005, 16:2296-2305.
66. Thomas W.G., Brandenburger Y., Autelitano D.J., Pham T., Qian H., Hannan R.D. Adenoviral-directed expression of the type 1a angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ. Res. 2002, 90:135-142.
67. Touyz R.M., Wu X.H., He G., Salomon S., Schiffrin E.L. Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 2002, 39:479-485.
68. Wehling M. Nongenomic actions of steroid hormones. Trends. Endocrinol. Metab. 1994, 5:347-353.
69. Wehling M., Käsmayr J., Theisen K. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway?. Am. J. Physiol. 1991, 260:E719-E726.
70. Xiao F., Puddefoot J., Vinson G.P. Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J. Endocrinol. 2000, 165:533-536.
71. Yim H.E., Yoo K.H., Bae I.S., Jang G.Y., Hong Y.S., Lee J.W. Aldosterone regulates cellular turnover and mitogen-activated protein kinase family expression in the neonatal rat kidney. J. Cell. Physiol. 2009, 219:724-733.
72. Young M.J. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 2008, 17:174-180.
73. Zannad F., McMurray J.J.V., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., Vincent J., Pocock S.J., Pitt B. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N. Engl. J. Med. 2010, 364:11-21.
74. Zhang H., Chalothorn D., Jackson L.F., Lee D.C., Faber J.E. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ. Res. 2004, 95:989-997.
75. Zhang M., Chen J., Lai L., You L., Lin S., Hao C., Gu Y. Aldosterone promotes fibronectin synthesis in rat mesangial cells via ERK1/2-stimulated Na-H+ exchanger isoform 1. Am. J. Nephrol. 2010, 31:75-82.